In vitro characterization of new stabilizing albumin nanoparticles as a potential topical drug delivery system in the treatment of corneal neovascularization (CNV)

Llabot, Juan Manuel; Redín, Inés Luis de; Agüeros, Maite; Caballero, María José Dávila; Boiero, Carolina; Irache, Juan M.; Allemandi, Daniel Alberto

doi:10.1016/j.jddst.2019.04.042

Cited by 20 publications

(17 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…On the other hand, the preparation of human serum albumin nanoparticles to load bevacizumab with crosslinking agents as stabilizers, was explored. While human serum albumin nanoparticles crosslinked with glutaraldehyde did not resulted suitable to load bevacizumab due to the inactivation of the antibody after reacting with this crosslinking, 124 human serum albumin nanoparticles stabilized by Gantrez ® ES‐425 presented important payloads (97 μg/mg nanoparticle) of the active form of the antibody and a release profile characterized by a small burst effect followed by a sustained release rate 125 …”

Section: Nanoparticulate Systems For Bd Delivery Intended For Ocular mentioning

confidence: 99%

Biological drug therapy for ocular angiogenesis: Anti‐VEGF agents and novel strategies based on nanotechnology

Formica

Alfonso

Palma

2021

Pharmacology Res & Perspec

View full text Add to dashboard Cite

Currently, biological drug therapy for ocular angiogenesis treatment is based on the administration of anti‐VEGF agents via intravitreal route. The molecules approved with this purpose for ocular use include pegaptanib, ranibizumab, and aflibercept, whereas bevacizumab is commonly off‐label used in the clinical practice. The schedule dosage involves repeated intravitreal injections of anti‐VEGF agents to achieve and maintain effective concentrations in retina and choroids, which are administrated as solutions form. In this review article, we describe the features of different anti‐VEGF agents, major challenges for their ocular delivery and the nanoparticles in development as delivery system of them. In this way, several polymeric and lipid nanoparticles are explored to load anti‐VEGF agents with the aim of achieving sustained drug release and thus, minimize the number of intravitreal injections required. The main challenges were focused in the loading the molecules that maintain their bioactivity after their release from nanoparticulate system, followed the evaluation of them through studies of formulation stability, pharmacokinetic, and efficacy in in vitro and in vivo models. The analysis was based on the information published in peer‐reviewed published papers relevant to anti‐VEGF treatments and nanoparticles developed as ocular anti‐VEGF delivery system.

show abstract

Section: Nanoparticulate Systems For Bd Delivery Intended For Ocular mentioning

confidence: 99%

Biological drug therapy for ocular angiogenesis: Anti‐VEGF agents and novel strategies based on nanotechnology

Formica

Alfonso

Palma

2021

Pharmacology Res & Perspec

View full text Add to dashboard Cite

show abstract

“…100 nm ± 30 nm) which means an actual nanoparticle concentration of 90% from the initial protein concentration. Therefore, the gamma irradiation process for nanoparticle obtention means minimal protein degradation compared to albumin NP prepared by desolvation methods [21]. Study also shows less than 20% of nanoparticle aggregation.…”

Section: Structure Morphology and Sizementioning

confidence: 84%

Effect of structure in ionised albumin based nanoparticle: Characterisation, Emodin interaction, and in vitro cytotoxicity

Siri

Ruocco

Achilli

et al. 2019

Materials Science and Engineering: C

View full text Add to dashboard Cite

A γ-irradiated bovine albumin serum-based nanoparticle was characterised structurally, and functionally. The nanoparticle was characterised by A.F.M., D.L.S, zeta potential, T.E.M., gel-electrophoresis, and spectroscopy. We studied the stability of the nanoparticle at different pH values and against time, by fluorescence spectroscopy following the changes in the tryptophan environment in the nanoparticle. The nanoparticle was also functionalized with Folic Acid, its function as a nanovehicle was evaluated through its interaction with the hydrophobic drug Emodin. The binding and kinetic properties of the obtained complex were evaluated by biophysical methods as well as its toxicity in tumor cells. According to its biophysics, the nanoparticle is a spherical nanosized vehicle with a hydrodynamic diameter of 70 nm. Data obtained describe the nanoparticle as nontoxic for cancer cell lines. When combined with Emodin, the nanoparticle proved to be more active on MCF-7 cancer cell lines than the nanoparticle without Emodin. Significantly, the albumin aggregate preserves the main activity-function of albumin and improved characteristics as an excellent carrier of molecules. More than carrier properties, the nanoparticle alone induced an immune response in macrophages which may be advantageous in vaccine and cancer therapy formulation.

show abstract

“…As an alternative to glutaraldehyde due to its reactivity with the encapsulated drug and in vivo toxicity [ 102 , 103 ], monoalkyl ester of the copolymer of vinyl methyl ether and maleic anhydride has been proposed. For instance, BCZ-loaded human serum albumin nanoparticles stabilized by butyl ester of poly(vinyl methyl ether/maleic anhydride) (Gantrez ® ES-425, 90–150 kDa) by weak bonds on the nanoparticles surface [ 56 ] have been developed. The spherical nanoparticles ( d = 282 nm; ζ potential = −39.0 mV, and EE% = 99.5%) showed BCZ in vitro release with an initial burst (about 8%) followed by a sustained release (about 10%) within 1 h, totalizing 30% after 24 h in PBS medium.…”

Section: Development Of Nanoparticulate Drug Delivery Systems For Bczmentioning

confidence: 99%

“…Thus, the use of multiple emulsions (oil in water) in water (water/oil/water) was a strategy to improve the EE% of BCZ, resulting in values higher than 80% [ 43 , 45 , 46 ]. An EE% of almost 100% (99.5 ± 1.0%) was obtained for BCZ when encapsulated in human serum albumin nanoparticles and stabilized by a copolymer [ 56 ]. Comparing a similar formulation using glutaraldehyde as crosslinking agent in nanoparticles, a significant decrease in the BCZ entrapment (0.11 ± 0.3%) was observed.…”

Section: Limitations and Advantages Of Bcz Nanocarriersmentioning

confidence: 99%

“…Comparing a similar formulation using glutaraldehyde as crosslinking agent in nanoparticles, a significant decrease in the BCZ entrapment (0.11 ± 0.3%) was observed. Possibly, glutaraldehyde reacted with BCZ by aldol condensation or Michael-type addition [ 56 ]. BCZ-loaded albumin nanoparticles produced without a crosslinking agent resulted in a high EE% (89 ± 0%), probably due to protein-protein interactions between BCZ and albumin [ 57 ].…”

Section: Limitations and Advantages Of Bcz Nanocarriersmentioning

confidence: 99%

See 1 more Smart Citation

Organic Nanocarriers for Bevacizumab Delivery: An Overview of Development, Characterization and Applications

et al. 2021

View full text Add to dashboard Cite

Bevacizumab (BCZ) is a recombinant humanized monoclonal antibody against the vascular endothelial growth factor, which is involved in the angiogenesis process. Pathologic angiogenesis is observed in several diseases including ophthalmic disorders and cancer. The multiple administrations of BCZ can cause adverse effects. In this way, the development of controlled release systems for BCZ delivery can promote the modification of drug pharmacokinetics and, consequently, decrease the dose, toxicity, and cost due to improved efficacy. This review highlights BCZ formulated in organic nanoparticles providing an overview of the physicochemical characterization and in vitro and in vivo biological evaluations. Moreover, the main advantages and limitations of the different approaches are discussed. Despite difficulties in working with antibodies, those nanocarriers provided advantages in BCZ protection against degradation guaranteeing bioactivity maintenance.

show abstract

In vitro characterization of new stabilizing albumin nanoparticles as a potential topical drug delivery system in the treatment of corneal neovascularization (CNV)

Cited by 20 publications

References 36 publications

Biological drug therapy for ocular angiogenesis: Anti‐VEGF agents and novel strategies based on nanotechnology

Biological drug therapy for ocular angiogenesis: Anti‐VEGF agents and novel strategies based on nanotechnology

Effect of structure in ionised albumin based nanoparticle: Characterisation, Emodin interaction, and in vitro cytotoxicity

Organic Nanocarriers for Bevacizumab Delivery: An Overview of Development, Characterization and Applications

Contact Info

Product

Resources

About